New Dimensions Treatment Presentation Deck by Concord Business Plans

Investor Presentation 2021

Solutions Safely Securely New Dimensions Treatment Inc. Secure Telehealth Counselling & Treatment Protocol Utilizing Ketamine, & eventually MDMA & Psylocibin NEWDIMENSIONSTREATMENT.COM © 2021 New Dimensions Treatment Inc. – All Rights Reserved.

INVESTOR PRESENTATION 2021

DISCLAIMER

.02

This document contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the words “will”, “will be”, “finalizing”, “upgrading”, “to start”, “estimate”, “forecast”, “increase”, “anticipated”, “expected”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. This document contains forward-looking statements and assumptions pertaining to the following: business strategy, strength and focus; the granting of regulatory approvals and certifications; the timing for receipt of regulatory approvals and certifications; the Company’s ability to finalize leases related to production facilities; the Company’s ability to build and equip production facilities; the Company’s ability to obtain qualified staff and equipment in a timely and costefficient manner; supply and demand for the Company’s products; market prices for the Company’s products; the Company’s ability to deliver into existing product orders; the Company’s ability to increase production and deliver into anticipated future product orders; cash flow from sale of the Company’s products; use of proceeds related to potential financings; future capital expenditures to be made by the Company; and the Company’s ability to expand its product range. Actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth below and elsewhere in the document, such as the changes in the cost of operations, including costs of producing and delivering the Company’s products to market, that affect potential profitability; operating hazards and risks inherent in the Company’s operations; volatility in market prices for the Company’s products; market conditions that prevent the Company from raising the funds necessary for development and manufacturing on acceptable terms or at all; global financial market events that cause volatility in demand or pricing for the Company’s products; unexpected costs or liabilities for environmental matters; competition for, among other things, capital, acquisitions of feedstock, skilled personnel, and access to equipment and services required for manufacturing and production; changes in exchange rates or taxation rates; failure to realize the anticipated benefits of acquisitions; and other factors . Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in the document are expressly qualified by this cautionary statement. These statements speak only as of the date of this document and the Company does not undertake to update any forward-looking statements that are contained in this document, except in accordance with applicable securities laws.

Mental Health Issues

• Telehealth platform, AI assisted, proprietary, HIPAA compliant, 24/7 mental health support

• Providing multiple psychotherapeutic protocols (Patent Pending) utilizing Ketamine to solve chronic mental disorders • Psychotherapeutic solutions to improve mental health • Targeting PTSD, anxiety, depression, trauma, and suicidal issues

.03

VISION Connecting psychiatrists, therapists, psychologists and general practitioners to mental health patients utilizing a proprietary AI platform. Multiple psychotherapeutic protocols, ketamine assisted treatments that solve rather than medicate; mental disorders/trauma/ depression/PTSD/suicidal disorders, and anxiety etc.

.04

(180% remission on 4,000 chronic mental illness sufferers).

INVESTOR PRESENTATION 2021

.05

TELEHEALTH: A QUARTER-TRILLION-DOLLAR POST-COVID-19 REALITY 1

Telehealth utilization increased 78X times higher in April 2020 compared to Feb 2020.

64% of physicians view telehealth more favorably now than before Covid-19

11% of Consumers reported using Telehealth before Covid-19 (Siemens)

Now, in 2021, 76% of consumers are interested in using telehealth

TELEHEALTH USE HAS INCREASED 38X FROM THE PRE-COVID-19 BASELINE.

1McKinsey

& Co.

INVESTOR PRESENTATION 2021

.06

TELEMEDICINE GROWTH:

INVESTOR PRESENTATION 2021

OUR SERVICES

.07

Effective Solutions for Recovery from Mental Health Issues

CONNECT

CARE

CONSULT

DOCTORS

Connect securely by web, app or phone 24/7

Mental Health, Wellness & Recovery

PTSD, trauma, depression, anxiety, & suicidal treatment

Access to licensed psychiatrists, psychologists, Therapists & GPs

PRESCRIBE Multiple psychotherapeutic protocols, Ketamine assisted treatments

INVESTOR PRESENTATION 2021

BENEFITS OF TELEHEALTH

.08

Better Informed for Better Health

No transportation time or costs

No need to take time off work

Eliminate child or elder care issues

On-demand options

Access to Specialists

Less Chance of Catching a New Illness

24/7 Real Time Response

Better Health

INVESTOR PRESENTATION 2021

OUR VALUES DOCTORS Canada, USA & Australia licensed Psychologists, Psychiatrists, Therapists & GPs educated in New Dimensions proprietary protocol treatments

TELEHEALTH Connect virtually & securely to therapists Provide continuing support and health instructions Advanced confidentiality & communication security

PRESCRIPTIONS Doctors will diagnose, treat and prescribe Ketamine, and will add Psilocybin, and MDMA, when legally available

.09

ONGOING RECOVERY CARE Multiple psychotherapeutic protocols Ketamine assisted treatments solving mental health disorders, long term or short term as diagnosed

TECHNOLOGY PLATFORM Manage 24/7 access to doctors & patients Realtime communication & video conferencing Scheduling, consultation records & billing Easily scalable

IMPROVED EFFICIENCY Increase efficiency with configurable automation and digital tools, such as scheduling options, appointment reminders and digital files & forms

INVESTOR PRESENTATION 2021

ABOUT KETAMINE Combining Ketamine with Psychotherapy BENEFITS Ketamine works on depression and anxiety through various means, including direct amelioration of symptoms, promotion of neuroplasticity, as well as allowing patients to have more direct access to emotions, thus allowing them to resolve the traumatic issues which so often are resistant to conventional medications and psychotherapy.

LEGALITY IN CANADA Ketamine is a schedule 1 drug under the Controlled Substances Act and can be legitimately prescribed as an off-label medicine for psychiatric purposes. A sizeable minority of mental health prescriptions are off-label.

LEGALITY IN USA The FDA has approved use of ketamine for treatment resistant depression and ketamine can also be prescribed off-label for most mental health disorders for which a clinical rationale can be made.).

RESEARCH A great deal of research has indicated that ketamine is able to treat resistant depression, trauma (including PTSD), and various forms of anxiety, in a safe and effective manner.

.10

INVESTOR PRESENTATION 2021

TECHNOLOGY PLATFORM Best in class for client confidentiality, data security, authentication Compliance with relevant government regulatory authorities

TeleDoctoring

Proprietary, psychotherapeutic protocols (patent pending) utilizing Ketamine for solving mental disorders

Advanced Security Data Security - Designated Access Patient/Doctor Confidentiality Ensured Security Standards Audit

.11

Convenient Access Identification - Authentication - Authorization - Compliant

Compliance

Policies and Procedures in line with HIPAA & PHIPA Privacy, Security, and Breach Notification Rules

Ease of Use

Simple, Intuitive & Effective Interface Usability Tested

Find a Doctor USA, Canadian & Australian licensed doctors, psychologists & psychiatrists

I N V E S T O R P R E S E N T A T IO N 2 0 2 1

MARKETING

.12

Market to Clients Major News Media Branding Social media Conferences Community Outreach

Market to Doctors Medical Networking Organic Growth Medical Publications & Journals Medical Conferences National & Local SEO

Market to Investors Ongoing IR/PR investor programs Broad reach in investment community as the leader in this new paradigm

INVESTOR PRESENTATION 2021

FOUNDERS, DIRECTORS & MANAGEMENT SEASONED EXECUTIVES Marc Kipnes

Shayne Nyquvest

Joe Devries

Director

Co-Founder, Director

Director, Finance

Career raising $millions for construction & automobile sectors. Founder, Karma Developments $250m in sales

Over 30 years leadership experience in investment banking, finance, and M&A

Over 30 years experience arranging financing, and administering public companies

Paul Lathigee

Chris Kimbrell

Dr. Ravi Pal Bains

Angelo De Gioannis

Co-Founder, Corp Dev

President

Medical Director

CPO (in Process)

Navy Seal 20 years Diverse private sector development with a focus on high performance teams

CMO, Wayfound Mental Health ATMA Journey Centers Leader in ketamine assisted psychotherapeutic protocols

Financed & advised over 30 growth public companies. Originated multiple successful startups

.13

Chief Psychedelic Officer Pioneering mental health treatments, ketamine assisted psychotherapeutic protocols

INVESTOR PRESENTATION 2021

ADVISORY

.14

SEASONED EXECUTIVES Dr. Riaan Van Der Wart

Dr. Matthew Campeau

Dr. Mark Braunstein

Medical Doctor

US Medical Advisor

ER and Family Physician treating addiction and depression in First Nations communities

Psychotherapist Clinical Assessor Multidisciplinary Association for Psychedelic Studies 10 yrs.

PhD, Psychiatry CEO at Reconscious Medical Pioneer in ketamine assisted psychotherapeutic protocols

Theoren Fleury

Concord Business

Brent Bryski

Advisory

Technology Advisor

Advisor

Stanley Cup & Olympic Gold Medal winning hockey player who overcame drug and alcohol addictions

Senior Security Engineering Infrastructure Security, Coding Authentication and Identity, Ruby, C, JS, Python, PHP etc.

CEO of Klinix Software for medical billing HIPPA & PHIPA Compliance

INVESTOR PRESENTATION 2021

FINANCING SOUGHT

.15

$4,350,000

New Dimensions Treatment Inc. Capital Structure Total Escrow @ $0.01 per share

25,000,000 shares

$250,000

Total @ $0.025 per share

24,000,000 shares

$600,000

Management Earn Out Escrow @ $0.10

10,000,000 shares

Total @ $0.10 per share

25,000,000 shares

$2,500,000

MD Participation A @ $0.10

10,000,000 shares

$1,000,000

Total

94,000,000 shares

$4,350,000

INVESTOR PRESENTATION 2021

REVENUE PROJECTIONS Total Revenues and Operating Income – 3 Years

TOTAL REVENUES & OPERATING INCOME Total Revenues $50,000,000 $40,000,000 $30,000,000 $20,000,000 $10,000,000 $$(10,000,000)

PROFITABILITY & ROI

Operating Income (EBITDA) Revenue Gross Margin Gross Margin (%) Net Income Net Profit Margin (%) Initial Investment Yearly ROI

YEAR 1

YEAR 2

YEAR 3

Average ROI

$ $ $ $

Year 1 3,600,000 720,000 20% (1,720,000) -47.78% 1,700,000 -101.2%

253.03%

Doctors will be contracted and have the opportunity for long-term earn-in equity

.16

Year 2 $ 20,160,000 $ 4,032,000 20% $ 865,600 4% $ 50.9%

Year 3 $ 42,480,000 $ 8,496,000 20% $ 4,201,600 10% $ 247.2%

CONTACT US 595 Howe Street, Suite 303 Vancouver BC V6C 2T5 +1 (604) 336-8613 paul@ndttelehealth.com www.newdimensionstreatment.com

.17